You are here

Phase 2 Study Evaluates Squalamine Lactate in Wet Age-Related Macular Degeneration

PLYMOUTH MEETING, Pa., June 26 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced that the first patient has been enrolled in a multi-center, open-label, pharmacodynamic Phase II clinical trial, MSI-1256F-212 ("Study 212"), to explore the efficacy and safety of EVIZON(TM) (squalamine lactate) at higher doses. Study 212 is designed to evaluate up to 140 patients with wet age-related macular degeneration ("AMD") treated with EVIZON(TM) at four dose levels (40 mg, 80 mg, 120 mg and 160 mg) over a 20 week period.

"Genaera is pleased to announce the beginning of active enrollment in Study 212," commented Jack Armstrong, President and Chief Executive Officer. "We have assembled an outstanding group of investigators and study sites and are looking forward to obtaining additional information on the most effective dose of EVIZON. This study will provide more detailed information on EVIZON's effects on visual acuity in both affected eyes of patients with exudative AMD. There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections. EVIZON is differentiated from other competitor drugs having demonstrated a positive effect in both study and fellow affected eyes in previous clinical trials. We look forward to confirming that EVIZON is the treatment to meet that medical need."

For information about participation in EVIZON(TM) clinical trials, patients and physicians may call Genaera's Clinical Trial Hotline at (800) 299-9156.

Source: Genaera Corporation

Recent Headlines

Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Patients Had Improved Lung Function, Fewer Exacerbations
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile